VEGFA and pulmonary arterial hypertension: Hypertension, arterial thromboembolism, pulmonary hypertension, cardiac ischemia, and QT prolongation are the main adverse effects associated with VEGF-inhibiting agents.138,139 Cardiomyopathy is a relatively infrequent adverse event of VEGF inhibitors in the absence of additional insults and may predominantly occur when other cardiovascular adverse event ensue (i.e. severe hypertension).